 Cindy O'Bryant
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 22 | 2025 | 2111 | 1.890 |
Why?
| | Neoplasms | 32 | 2025 | 2698 | 1.680 |
Why?
| | Antiemetics | 2 | 2024 | 44 | 0.840 |
Why?
| | Pyridines | 5 | 2015 | 497 | 0.830 |
Why?
| | Piperidines | 3 | 2021 | 207 | 0.790 |
Why?
| | Pharmacists | 5 | 2025 | 262 | 0.730 |
Why?
| | Indazoles | 1 | 2021 | 67 | 0.690 |
Why?
| | Anilides | 2 | 2013 | 70 | 0.690 |
Why?
| | Liver | 3 | 2021 | 1867 | 0.670 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 42 | 0.620 |
Why?
| | Immunoconjugates | 2 | 2023 | 115 | 0.620 |
Why?
| | Cisplatin | 5 | 2024 | 320 | 0.610 |
Why?
| | Morpholines | 1 | 2020 | 121 | 0.610 |
Why?
| | Drug Hypersensitivity | 1 | 2020 | 91 | 0.580 |
Why?
| | Drug Interactions | 6 | 2024 | 400 | 0.540 |
Why?
| | Protein Kinase Inhibitors | 5 | 2024 | 901 | 0.530 |
Why?
| | Carcinoma, Basal Cell | 2 | 2017 | 73 | 0.510 |
Why?
| | Histone Deacetylase Inhibitors | 3 | 2019 | 208 | 0.500 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2015 | 231 | 0.440 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2020 | 1680 | 0.430 |
Why?
| | Medical Oncology | 3 | 2025 | 299 | 0.410 |
Why?
| | Dose-Response Relationship, Drug | 13 | 2021 | 2015 | 0.400 |
Why?
| | Depsipeptides | 1 | 2012 | 14 | 0.390 |
Why?
| | Quinazolines | 2 | 2011 | 249 | 0.390 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2012 | 43 | 0.380 |
Why?
| | Pyrazoles | 2 | 2013 | 421 | 0.370 |
Why?
| | Area Under Curve | 8 | 2021 | 303 | 0.360 |
Why?
| | Sulindac | 2 | 2008 | 16 | 0.350 |
Why?
| | Neuroendocrine Tumors | 1 | 2012 | 105 | 0.350 |
Why?
| | Sirolimus | 1 | 2012 | 268 | 0.340 |
Why?
| | Nitriles | 2 | 2008 | 174 | 0.340 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 427 | 0.330 |
Why?
| | Skin Neoplasms | 2 | 2017 | 842 | 0.320 |
Why?
| | Aged | 30 | 2024 | 23803 | 0.310 |
Why?
| | Middle Aged | 33 | 2024 | 33226 | 0.310 |
Why?
| | Tosyl Compounds | 1 | 2008 | 14 | 0.300 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 57 | 0.290 |
Why?
| | Drug Dosage Calculations | 1 | 2008 | 22 | 0.280 |
Why?
| | Liver Failure, Acute | 1 | 2008 | 65 | 0.280 |
Why?
| | Bone Density Conservation Agents | 1 | 2008 | 80 | 0.280 |
Why?
| | Androgen Antagonists | 1 | 2008 | 86 | 0.280 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 1100 | 0.270 |
Why?
| | Pain | 3 | 2011 | 750 | 0.260 |
Why?
| | Breast Neoplasms | 3 | 2023 | 2266 | 0.260 |
Why?
| | Food | 1 | 2008 | 167 | 0.260 |
Why?
| | Fasting | 1 | 2008 | 282 | 0.250 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7559 | 0.250 |
Why?
| | Humans | 51 | 2025 | 136965 | 0.240 |
Why?
| | Liver Diseases | 2 | 2019 | 300 | 0.240 |
Why?
| | Acute Kidney Injury | 3 | 2018 | 802 | 0.240 |
Why?
| | Osteoporosis | 1 | 2008 | 241 | 0.230 |
Why?
| | Professional Role | 2 | 2017 | 166 | 0.230 |
Why?
| | Administration, Oral | 5 | 2012 | 783 | 0.230 |
Why?
| | Serotonin 5-HT3 Receptor Antagonists | 1 | 2024 | 5 | 0.230 |
Why?
| | Female | 35 | 2025 | 73002 | 0.230 |
Why?
| | Deoxycytidine | 5 | 2011 | 186 | 0.230 |
Why?
| | Platinum | 1 | 2024 | 50 | 0.220 |
Why?
| | Pancreatic Neoplasms | 1 | 2012 | 832 | 0.220 |
Why?
| | Maximum Tolerated Dose | 10 | 2020 | 199 | 0.220 |
Why?
| | Adult | 28 | 2025 | 37715 | 0.220 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1412 | 0.220 |
Why?
| | Hedgehog Proteins | 2 | 2017 | 197 | 0.210 |
Why?
| | Male | 34 | 2025 | 67386 | 0.210 |
Why?
| | Nausea | 4 | 2020 | 111 | 0.210 |
Why?
| | Midazolam | 1 | 2024 | 56 | 0.210 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2024 | 88 | 0.210 |
Why?
| | Angiogenesis Inhibitors | 4 | 2010 | 227 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2017 | 798 | 0.200 |
Why?
| | Lung Neoplasms | 2 | 2015 | 2552 | 0.200 |
Why?
| | Vomiting | 3 | 2020 | 131 | 0.190 |
Why?
| | Sulfonamides | 2 | 2019 | 507 | 0.180 |
Why?
| | Cohort Studies | 5 | 2020 | 5688 | 0.170 |
Why?
| | ErbB Receptors | 2 | 2017 | 606 | 0.170 |
Why?
| | Lymphoma | 2 | 2016 | 209 | 0.170 |
Why?
| | Trastuzumab | 2 | 2023 | 96 | 0.170 |
Why?
| | Pyrimidines | 2 | 2024 | 465 | 0.170 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2023 | 203 | 0.170 |
Why?
| | Prostatic Neoplasms | 1 | 2008 | 1041 | 0.170 |
Why?
| | Apoptosis | 3 | 2008 | 2542 | 0.170 |
Why?
| | Fluorouracil | 4 | 2011 | 198 | 0.170 |
Why?
| | Benzoxazoles | 1 | 2020 | 19 | 0.170 |
Why?
| | Drug Evaluation | 1 | 2020 | 80 | 0.160 |
Why?
| | Patient Care Team | 1 | 2025 | 630 | 0.160 |
Why?
| | Azepines | 1 | 2020 | 97 | 0.160 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1365 | 0.160 |
Why?
| | Analgesics, Opioid | 1 | 2008 | 1039 | 0.150 |
Why?
| | Hydroxamic Acids | 1 | 2019 | 88 | 0.150 |
Why?
| | TWEAK Receptor | 1 | 2017 | 5 | 0.140 |
Why?
| | Pharmacogenomic Variants | 1 | 2017 | 33 | 0.130 |
Why?
| | Models, Biological | 1 | 2024 | 1780 | 0.130 |
Why?
| | Hematology | 1 | 2017 | 19 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2014 | 545 | 0.130 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 49 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2020 | 504 | 0.130 |
Why?
| | Pharmaceutical Services | 1 | 2017 | 85 | 0.130 |
Why?
| | Maytansine | 1 | 2016 | 17 | 0.120 |
Why?
| | Pain Management | 2 | 2017 | 363 | 0.120 |
Why?
| | Aminoglycosides | 1 | 2016 | 24 | 0.120 |
Why?
| | Specialty Boards | 1 | 2016 | 35 | 0.120 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2809 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2017 | 314 | 0.120 |
Why?
| | Drugs, Investigational | 1 | 2015 | 32 | 0.120 |
Why?
| | Carbazoles | 1 | 2015 | 47 | 0.110 |
Why?
| | Biomarkers, Tumor | 4 | 2010 | 1229 | 0.110 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 97 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2016 | 114 | 0.110 |
Why?
| | American Heart Association | 1 | 2016 | 301 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 436 | 0.110 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2014 | 16 | 0.110 |
Why?
| | Insurance Claim Review | 1 | 2014 | 68 | 0.110 |
Why?
| | Drug Administration Schedule | 5 | 2019 | 749 | 0.100 |
Why?
| | Carboplatin | 3 | 2009 | 142 | 0.100 |
Why?
| | Chronic Pain | 1 | 2017 | 271 | 0.100 |
Why?
| | Specialization | 1 | 2014 | 147 | 0.100 |
Why?
| | Gonanes | 1 | 2012 | 27 | 0.100 |
Why?
| | Everolimus | 1 | 2012 | 88 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2010 | 348 | 0.090 |
Why?
| | Signal Transduction | 2 | 2017 | 5047 | 0.090 |
Why?
| | Biomarkers | 3 | 2018 | 4095 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1019 | 0.090 |
Why?
| | Erlotinib Hydrochloride | 1 | 2011 | 68 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2013 | 208 | 0.090 |
Why?
| | Liver Function Tests | 1 | 2011 | 106 | 0.090 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 839 | 0.090 |
Why?
| | Phytotherapy | 1 | 2011 | 84 | 0.090 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 281 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2020 | 15536 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 738 | 0.080 |
Why?
| | Glucuronidase | 2 | 2008 | 43 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 998 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 2014 | 495 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 43 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2011 | 495 | 0.080 |
Why?
| | Oligosaccharides | 2 | 2008 | 61 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 86 | 0.080 |
Why?
| | Treatment Outcome | 7 | 2015 | 10664 | 0.080 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 30 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2456 | 0.080 |
Why?
| | Kidney | 1 | 2017 | 1466 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 406 | 0.080 |
Why?
| | Cannabinoids | 1 | 2011 | 167 | 0.080 |
Why?
| | Clinical Competence | 1 | 2017 | 1114 | 0.080 |
Why?
| | Primary Health Care | 2 | 2017 | 1775 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 630 | 0.080 |
Why?
| | Capecitabine | 4 | 2011 | 41 | 0.070 |
Why?
| | Education, Pharmacy, Continuing | 1 | 2008 | 3 | 0.070 |
Why?
| | Equipment and Supplies | 1 | 2008 | 42 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 77 | 0.070 |
Why?
| | Taxoids | 2 | 2008 | 101 | 0.070 |
Why?
| | Boronic Acids | 1 | 2008 | 35 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1543 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2008 | 72 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2008 | 46 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 295 | 0.070 |
Why?
| | Marijuana Smoking | 1 | 2011 | 254 | 0.070 |
Why?
| | Farnesyltranstransferase | 1 | 2007 | 34 | 0.070 |
Why?
| | Etoposide | 1 | 2008 | 158 | 0.070 |
Why?
| | Drug Prescriptions | 1 | 2010 | 258 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2008 | 82 | 0.070 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 63 | 0.070 |
Why?
| | Reference Standards | 1 | 2008 | 183 | 0.070 |
Why?
| | Receptors, Vitronectin | 1 | 2007 | 9 | 0.070 |
Why?
| | Administration, Cutaneous | 1 | 2008 | 128 | 0.070 |
Why?
| | Integrin alphaVbeta3 | 1 | 2007 | 18 | 0.070 |
Why?
| | Pyrazines | 1 | 2008 | 85 | 0.070 |
Why?
| | Oxycodone | 1 | 2008 | 48 | 0.070 |
Why?
| | Snake Venoms | 1 | 2007 | 22 | 0.070 |
Why?
| | Absorptiometry, Photon | 1 | 2008 | 264 | 0.070 |
Why?
| | Benzamides | 1 | 2008 | 209 | 0.070 |
Why?
| | Triazoles | 1 | 2008 | 150 | 0.070 |
Why?
| | Fatigue | 4 | 2012 | 337 | 0.070 |
Why?
| | Indoles | 2 | 2008 | 406 | 0.070 |
Why?
| | Delayed-Action Preparations | 1 | 2008 | 173 | 0.070 |
Why?
| | Pharmacogenetics | 1 | 2008 | 165 | 0.060 |
Why?
| | Integrins | 1 | 2007 | 95 | 0.060 |
Why?
| | Fentanyl | 1 | 2008 | 97 | 0.060 |
Why?
| | Anxiety Disorders | 1 | 2010 | 375 | 0.060 |
Why?
| | Animals | 6 | 2020 | 36882 | 0.060 |
Why?
| | Morphine | 1 | 2008 | 158 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2007 | 131 | 0.060 |
Why?
| | Methadone | 1 | 2008 | 99 | 0.060 |
Why?
| | Young Adult | 3 | 2020 | 13218 | 0.060 |
Why?
| | Thiophenes | 1 | 2007 | 117 | 0.060 |
Why?
| | Alkyl and Aryl Transferases | 1 | 2006 | 52 | 0.060 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 107 | 0.060 |
Why?
| | Cell Line, Tumor | 3 | 2020 | 3393 | 0.060 |
Why?
| | Palliative Care | 2 | 2011 | 812 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 577 | 0.060 |
Why?
| | Societies, Pharmaceutical | 2 | 2017 | 21 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 486 | 0.060 |
Why?
| | Nigeria | 1 | 2025 | 23 | 0.060 |
Why?
| | Risk Factors | 1 | 2020 | 10363 | 0.060 |
Why?
| | Protein Binding | 1 | 2011 | 2223 | 0.060 |
Why?
| | Granisetron | 1 | 2024 | 6 | 0.060 |
Why?
| | Quinuclidines | 1 | 2024 | 9 | 0.060 |
Why?
| | Ondansetron | 1 | 2024 | 16 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 538 | 0.060 |
Why?
| | Isoquinolines | 1 | 2024 | 43 | 0.060 |
Why?
| | Hypertension | 1 | 2014 | 1299 | 0.060 |
Why?
| | Quinolones | 1 | 2006 | 134 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 862 | 0.060 |
Why?
| | Occupational Exposure | 1 | 2008 | 342 | 0.060 |
Why?
| | United States | 5 | 2017 | 14945 | 0.060 |
Why?
| | Infusions, Intravenous | 2 | 2019 | 392 | 0.050 |
Why?
| | Cannabis | 1 | 2011 | 495 | 0.050 |
Why?
| | RNA, Catalytic | 1 | 2005 | 188 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 5812 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 743 | 0.050 |
Why?
| | Prospective Studies | 3 | 2024 | 7512 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 791 | 0.050 |
Why?
| | Heart Failure | 1 | 2016 | 2046 | 0.050 |
Why?
| | Camptothecin | 1 | 2023 | 114 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2015 | 2115 | 0.050 |
Why?
| | Pyrroles | 1 | 2024 | 212 | 0.050 |
Why?
| | Diarrhea | 2 | 2015 | 183 | 0.050 |
Why?
| | Adolescent | 2 | 2020 | 21471 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1460 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 341 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1352 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2020 | 56 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 125 | 0.040 |
Why?
| | Neutropenia | 2 | 2009 | 152 | 0.040 |
Why?
| | Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.030 |
Why?
| | Glutathione S-Transferase pi | 1 | 2017 | 10 | 0.030 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2017 | 34 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2018 | 318 | 0.030 |
Why?
| | Organic Cation Transport Proteins | 1 | 2017 | 25 | 0.030 |
Why?
| | Partial Thromboplastin Time | 2 | 2008 | 53 | 0.030 |
Why?
| | Anemia | 2 | 2009 | 171 | 0.030 |
Why?
| | Amidine-Lyases | 1 | 1997 | 1 | 0.030 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2007 | 27 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2008 | 5530 | 0.030 |
Why?
| | Mixed Function Oxygenases | 1 | 1997 | 46 | 0.030 |
Why?
| | Multienzyme Complexes | 1 | 1997 | 68 | 0.030 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 1997 | 55 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 157 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2017 | 109 | 0.030 |
Why?
| | Paclitaxel | 2 | 2009 | 236 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 1007 | 0.030 |
Why?
| | Cardiotoxins | 1 | 2015 | 3 | 0.030 |
Why?
| | Drug Eruptions | 1 | 2015 | 26 | 0.030 |
Why?
| | Mucositis | 1 | 2015 | 19 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 370 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2017 | 127 | 0.030 |
Why?
| | Analgesics | 1 | 1997 | 208 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5048 | 0.030 |
Why?
| | Pharmacy Residencies | 1 | 2014 | 11 | 0.030 |
Why?
| | Drug Discovery | 1 | 2015 | 144 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1706 | 0.030 |
Why?
| | Students, Pharmacy | 1 | 2014 | 100 | 0.020 |
Why?
| | Stroke Volume | 1 | 2015 | 571 | 0.020 |
Why?
| | Electrocardiography | 1 | 2015 | 607 | 0.020 |
Why?
| | Dioxoles | 1 | 2011 | 9 | 0.020 |
Why?
| | Tetrahydroisoquinolines | 1 | 2011 | 8 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2016 | 567 | 0.020 |
Why?
| | Biological Availability | 1 | 2011 | 133 | 0.020 |
Why?
| | Mice | 3 | 2020 | 17705 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 366 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3556 | 0.020 |
Why?
| | Massage | 1 | 2010 | 42 | 0.020 |
Why?
| | Alopecia | 1 | 2009 | 32 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 70 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3931 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2014 | 648 | 0.020 |
Why?
| | Celecoxib | 1 | 2008 | 39 | 0.020 |
Why?
| | Bortezomib | 1 | 2008 | 51 | 0.020 |
Why?
| | Maximum Allowable Concentration | 1 | 2008 | 16 | 0.020 |
Why?
| | Floxuridine | 1 | 2008 | 5 | 0.020 |
Why?
| | Protein Kinase C beta | 1 | 2008 | 20 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2010 | 268 | 0.020 |
Why?
| | Platelet Factor 4 | 1 | 2008 | 35 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2008 | 87 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2007 | 124 | 0.020 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2007 | 15 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2008 | 123 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2007 | 56 | 0.020 |
Why?
| | Protein Prenylation | 1 | 2006 | 34 | 0.020 |
Why?
| | Carcinoid Tumor | 1 | 2006 | 22 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2006 | 28 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2008 | 254 | 0.020 |
Why?
| | Heparin | 1 | 2008 | 250 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2008 | 197 | 0.020 |
Why?
| | Cell Adhesion Molecules | 1 | 2007 | 176 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2006 | 92 | 0.020 |
Why?
| | Risk | 1 | 2008 | 901 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 207 | 0.010 |
Why?
| | Inflammation | 1 | 1997 | 2831 | 0.010 |
Why?
| | Fibroblast Growth Factors | 1 | 2006 | 176 | 0.010 |
Why?
| | Antibody Formation | 1 | 2006 | 294 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1215 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 107 | 0.010 |
Why?
| | Monocytes | 1 | 2008 | 562 | 0.010 |
Why?
| | Disease Progression | 1 | 2012 | 2708 | 0.010 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 247 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2006 | 214 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 190 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1746 | 0.010 |
Why?
| | Gene Expression | 1 | 2007 | 1480 | 0.010 |
Why?
| | Gastrointestinal Tract | 1 | 2004 | 202 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2007 | 784 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3975 | 0.010 |
Why?
| | Melanoma | 1 | 2006 | 760 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2006 | 812 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3574 | 0.010 |
Why?
| | Carrageenan | 1 | 1997 | 8 | 0.010 |
Why?
| | Bradykinin | 1 | 1997 | 46 | 0.010 |
Why?
| | Substance P | 1 | 1997 | 36 | 0.010 |
Why?
| | Lyases | 1 | 1997 | 14 | 0.010 |
Why?
| | Edema | 1 | 1997 | 129 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1997 | 383 | 0.010 |
Why?
| | Serotonin | 1 | 1997 | 321 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6786 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1635 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1997 | 2139 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1997 | 2463 | 0.010 |
Why?
| | Rats | 1 | 1997 | 5544 | 0.000 |
Why?
|
|
O'Bryant's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|